Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

quote:

lower schreef op 30 januari 2017 13:02:

[...]

Gepland:

• https://www.pharming.com/investor-media/corporate-calendar-2017/
  -Event Date Time
  Full Year Results 9th of March 2017 07:00 CET
  First Quarter Results (1Q/2017) 17th of May 2017 07:00 CET
  Half Year Results (1H/2017) 27th of July 2017 07:00 CET
  9 Month Results (9M/2017) 26th of October 2017 07:00 CET

Aangekondigd:

• Update pipeline hebben we nog te goed van vorig jaar, er werd gesproeken over een R&D dag. prospectus p 64 meest reecnte info
  www.pharming.com/downloads/prospectus...

• -Aankoop antibodyprogramma

• -Ergens Q1, uitkomst FDA mbt gesprek hoe om te gaan met label voor Ruconest profylactisch.
  
  Pharming heeft zelf tot nu steeds aangegeven dat men een Phase3 onderzoek verwacht[/b]
  Het rapport van Roth geeft dat ook aan en dat de Phase3 in 2020 wordt opgestart.
  Hopelijk heeft Pharming zich hierin goed verdiept:
  Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review
  www.fda.gov/forpatients/approvals/fas...
  
  Should the FDA Approve More Drugs after Phase II?
  www.forbes.com/sites/aroy/2012/05/04/...
  

Toevoeging

• In February 2012, Pharming entered into a commercialisation partnership with Transmedic for the commercialisation of RUCONEST® in Brunei, Indonesia, Malaysia, Philippines, Singapore, and Thailand for the treatment of acute HAE attacks in patients. This partnership will end in February 2017
  www.pharming.com/downloads/prospectus...
  p70

quote:

lower schreef op 31 januari 2017 16:50:

[...]

quote:

lower schreef op 31 januari 2017 16:57:

Stifel 3-12-2016
0,66 euro
www.pharming.com/wp-content/uploads/2...

S First Berlin 28-10-2016
1,2 euro
www.more-ir.de/d/14645.pdf

Roth 24-01-2017
1,5 euro
www.pharming.com/wp-content/uploads/2...

quote:

't zal maar gebeuren schreef op 31 januari 2017 16:32:

By Damian Paletta
WASHINGTON -- President Donald Trump on Tuesday told pharmaceutical chief executives that he wanted them to bring drug prices "way down," but he promised them he would curb regulations and lower tax rates to boost their competitiveness.
At a White House meeting, Mr. Trump said Medicare and Medicaid are spending too much money on drugs, and he said in many cases these federal programs don't have enough bargaining power when they are purchasing drugs.
"We have to get prices down for a lot of reasons," Mr. Trump told the executives. "We have no choice. For Medicare, for Medicaid. We have to get the prices way down."
Mr. Trump said there was "price fixing by the biggest dog in the market -- Medicare," and said this must stop. He said, for example, that he could buy aspirin more cheaply at a pharmacy than the U.S. would pay for the same product.
The morning meeting between Mr. Trump and the executives is one in a series of gatherings he has held with business leaders and others during his first two weeks in office, as he works to find more ways to boost economic growth.
He added that he would be working to scale back regulations he said force pharmaceutical companies to spend years and billions of dollars developing drugs before they can get federal approval. He said he would soon nominate someone to head the Food and Drug Administration who would help with this overhaul.
"Instead of 9,000 pages, 100 pages," Mr. Trump said, offering an illustration of how the regulations would be scaled back.
Mr. Trump said that foreign countries are "freeloading" off the way the U.S. government allows drug companies to be developed here and then sold overseas at unfairly low prices and also by devaluing their currencies.
"We sit there like a bunch of dummies," he said.
Finally, Mr. Trump said he would pressure these companies to do more of their manufacturing in the U.S. instead of overseas. He said the business climate in the U.S. will change soon in part because he is committed to lowering the corporate tax rate and streamlining regulations. Pharmaceutical companies traditionally pay a low tax rate because of the way they structure their businesses, but they have still pushed hard for a lower rate for years.
During the meeting, Robert Bradway, chief executive of Amgen Inc., told Mr. Trump that his company would be "adding 1,600 jobs" in the U.S. this year, something the president praised.
Write to Damian Paletta at damian.paletta@wsj.com
(END) Dow Jones Newswires
January 31, 2017 10:27 ET (15:27 GMT)
© 2017 Dow Jones & Company, Inc.

quote:

kippekop schreef op 31 januari 2017 20:02:

Heb nog wat cash..........dus.

quote:

voda schreef op 31 januari 2017 20:07:

[...]
Buy Gold!

(Trump zit al heel lang in goud!), dus.... :-)

myfirstclasslife.com/inside-donald-tr...

quote:

kippekop schreef op 31 januari 2017 20:15:

[...]

Trump barst van de schulden.
De banken moeten hem wel geld blijven geven, anders stort het hele zaakje in.

quote:

voda schreef op 31 januari 2017 20:20:

[...]
Ach ja! Waarom denk je dat hij zijn belasting aangifte niet openbaar maakt?

Daaruit zou blijken dat hij amper belasting betaalt, sterker nog, dat de rest van de Amerikanen voor zijn "geleden" verliezen betaalt!!

De man is niet voor niets zo 'rijk" geworden. En dat leidt nu Amerika naar de "ondergang". Helaas sleurt hij weer miljoenen mensen of meer, de ondergang in....